{'fraction_non_alphanumeric': 0.020850040096230954, 'fraction_numerical': 0.008821170809943865, 'mean_word_length': 5.087804878048781, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Finnish Experiences with Carbamazepine (Tegretol ®) in the Treatment of Acute Withdrawal Symptoms in Alcoholics

The drinking problem in Finnish society is far from uncommon and has worsened with an increase in economic welfare. Measures have, therefore, been tried in the struggle against the different consequences of alcohol misuse. Efforts are being made all over the world to find an effective drug for the treatment of the alcohol withdrawal syndrome. During the last few years we have performed a series of clinical trials to study the use of carbamazepine (CBZ) in the alcohol withdrawal syndrome. In a multicentre trial (Bjorkqvist et al1976) 105 male out-patients, aged 20-60 years, who had voluntarily sought treatment for alcohol withdrawal symptoms at five Finnish A-clinics or alcoholism treatment centres were entered into the study. They had been taking alcohol for at least three last days prior to entry and were not misusers of drugs or chronic narcotics, neither had they heart, liver or renal insufficiency. They were not taking antihypertensive treatment or any other preparations acting on the CNS. The patients were randomly allocated to two treatments, CBZ and placebo, a doubleblind technique being employed. The patients